Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

SHE:300357 China Drug Manufacturers - General
Market Cap
$1.79 Billion
CN¥13.13 Billion CNY
Market Cap Rank
#7780 Global
#1375 in China
Share Price
CN¥25.07
Change (1 day)
+0.04%
52-Week Range
CN¥19.38 - CN¥35.30
All Time High
CN¥5101.55
About

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: 0.032x

Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a cash flow conversion efficiency ratio of 0.032x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥88.11 Million) by net assets (CN¥2.73 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥2.46 Billion CN¥262.44 Million 0.107x -36.68%
2023-12-31 CN¥2.30 Billion CN¥388.32 Million 0.169x -5.16%
2022-12-31 CN¥2.03 Billion CN¥360.28 Million 0.178x -11.44%
2021-12-31 CN¥1.80 Billion CN¥360.58 Million 0.201x +19.70%
2020-12-31 CN¥1.53 Billion CN¥256.22 Million 0.168x -2.68%
2019-12-31 CN¥1.35 Billion CN¥232.93 Million 0.172x -16.93%
2018-12-31 CN¥995.42 Million CN¥206.45 Million 0.207x +4.43%
2017-12-31 CN¥801.26 Million CN¥159.13 Million 0.199x +6.05%
2016-12-31 CN¥655.58 Million CN¥122.77 Million 0.187x -4.93%
2015-12-31 CN¥582.91 Million CN¥114.82 Million 0.197x +20.85%
2014-12-31 CN¥513.55 Million CN¥83.70 Million 0.163x -29.58%
2013-12-31 CN¥251.92 Million CN¥58.30 Million 0.231x +1.97%
2012-12-31 CN¥181.38 Million CN¥41.17 Million 0.227x +51.24%
2011-12-31 CN¥127.61 Million CN¥19.15 Million 0.150x -6.64%
2010-12-31 CN¥90.44 Million CN¥14.54 Million 0.161x +42.42%
2009-12-31 CN¥111.89 Million CN¥12.63 Million 0.113x --